Clinical trials

Covid-19
#Clinical trials #Covid-19 #Drug development #Oncology #Therapeutics

Oncology treatment tested in patients with moderate Covid-19 disease 

Australian clinical-stage drug development company Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate Covid-19 disease. Veyonda currently has two main drug actions – a moderating… Read More

#Covid-19 #News #Trending News

#Clinical trials #Drug development #FDA

FDA grant ODD for hyperammonemia in inborn errors of metabolism

Versantis’ lead product candidate VS-01 has been has granted orphan drug designation (ODD) by the Food and Drug Administration (FDA) for the treatment of hyperammonemia (HA) in inborn errors of metabolism (IEM).   “This orphan drug designation from the FDA validates the scientific rationale of VS-01 in a… Read More

#News

#Clinical trials #HIV #Immunology / Virology & Vaccines #Johnson & Johnson

J&J HIV vaccine candidate does not protect women against HIV infection 

An investigational HIV vaccine tested in the “Imbokodo” clinical trial conducted in sub-Saharan Africa did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. It posed no safety concerns. The Phase IIb proof-of-concept study, which began in November 2017, enrolled 2,637 women… Read More

#News #Trending News

Seed funding
#Clinical trials #Covid-19 #Drug discovery #Funding #Research #Therapeutics

ILC Therapeutics completes £3.5 million funding round 

ILC Therapeutics has completed a £3.5 million pre-IPO funding round. Investors include Robert Kopple, Eos Angel Investment Syndicate, Scottish Enterprise and ILCT management.  Chairman Peter Bains said: “With this funding in place, ILCT is now well positioned to strengthen its novel technology platform and to advance its lead candidate, Alfacyte… Read More

#Business & Investment #News

#Biopharmaceuticals #Clinical trials #Drug development #Drug discovery

Building a pipeline of clinically-differentiated cancer therapies 

As previously reported by DDW, Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. Megan Thomas speaks Dr Alastair Smith, Chief Executive Officer of Avacta Group, about this development.   MT: You previously commented that this study marks the… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#AstraZeneca #Clinical trials #Covid-19 #Immunology / Virology & Vaccines

SK bioscience and GSK start trial of Covid-19 vaccine 

SK bioscience (SK) and GlaxoSmithKline (GSK) have initiated a Phase III clinical study of SK’s Covid-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase I/II results.  The randomised, active-controlled global trial will enrol around 4,000 participants from a range of countries and will aim to… Read More

#News

#Autoimmune disease #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

NIH studies Covid-19 vaccine dose for people with autoimmune disease 

The National Institutes of Health (NIH) has begun a clinical trial to assess the antibody response to an extra dose of an authorised or approved Covid-19 vaccine in people with autoimmune disease who did not respond to an original Covid-19 vaccine regimen.   The trial will also investigate whether pausing… Read More

#Covid-19 #News #Trending News

#Cancer research #Clinical trials #Drug development #Drug discovery #Institute of Cancer Research

New cancer drug to enter first clinical trial targeting HSF1 pathway 

The Institute of Cancer Research (ICR), London has discovered an investigational drug called NXP800, which cancer patients are set to receive for the first time. It was discovered in a Phase I clinical trial sponsored by an oncology-focused biopharmaceutical company, Nuvectis Pharma.  The investigational oral drug inhibits the so-called… Read More

#Cancer Research #Trending News

#Biopharmaceutical #Clinical trials #Drug delivery #Drug development

First patient dosed in izokibep trial for patients with active AS

Inmagene Biopharmaceuticals and Affibody have dosed the first patient in the global ASPIRE Phase II trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of ankylosing spondylitis (AS).  “Dosing the first patient in the global Phase II AS trial is an important milestone for the izokibep programme,” said Dr. Jean-Louis Saillot, Inmagene’s Chief… Read More

#News

#Clinical trials #Diabetes #Drug development #Eye

Scientists prepare to trial new nano-drug for eye diseases 

Professor Di Yu of the UQ Diamantina Institute collaborated with scientists from the Chinese Academy of Sciences and Beijing Chaoyang Hospital to address age-related macular degeneration and retinal neovascularisation linked to diabetes, which affect approximately 450 million people worldwide. This has been published in Nature Biomedical Engineering.  Currently, treatments… Read More

#News

#Clinical trials #Covid-19

First doses issued in trial evaluating EOM613 in Covid-19 patients in Brazil

EOM Pharmaceuticals has dosed the first patient in R1: RESCUE, a proof-of-concept Phase I/IIa open-label multi-centre clinical study in Brazil to evaluate safety, tolerability, and preliminary efficacy of EOM613 in hospitalised Covid-19 infected patients with severe symptoms.   Irach B. Taraporewala, Chief Executive Officer and Director of EOM, said: “This is the first step… Read More

#News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Valneva begins submission to MHRA for its Covid-19 vaccine 

Valneva has begun a rolling submission for initial approval of its Covid-19 vaccine candidate, VLA2001, with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. VLA2001 is a whole virus, inactivated, adjuvanted vaccine candidate and is the only vaccine candidate of this type currently in clinical trials in… Read More

#Covid-19 #News #Trends & Analysis

#Cancer #Cancer research #Clinical trials #Drug repurposing

Aspirin trialled as potential treatment for aggressive breast cancer 

A new study is trialling whether giving aspirin alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer.   The clinical trial is being funded by the Breast Cancer Now Catalyst Programme, which aims to accelerate progress in breast cancer research through innovation and collaboration. As… Read More

#Cancer Research #News #Trending News

#Cancer immunotherapy #Cancer research #Clinical trials #Immuno-oncology #Immunology / Virology & Vaccines #Tumour biology

Collaboration to develop a novel cancer immunotherapy  

Terumo Blood and Cell Technologies and PhotonPharma have established a memorandum of understanding (MOU) for collaboration to develop Innocell, a novel tumour specific immunotherapy (a therapeutic vaccine)… Read More

#Cancer Research #News

Covid-19
#Clinical trials #Covid-19 #Immunotherapy #Moderna #mRNA #Pfizer

Study on third Covid-19 vaccine dose in kidney transplant recipients 

A pilot study has begun to assess the antibody response to a third dose of an authorised Covid-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech Covid-19 vaccine. The Phase II trial is sponsored and funded by the National Institute of Allergy and… Read More

#Covid-19 #News

#Clinical trials #Drug development #Drug discovery

Lung fibrosis drug may help heart failure patients 

An early phase trial of pirfenidone, a drug currently used to treat lung fibrosis, has shown it may also help patients who suffer from a common form of heart failure in a study funded by the National Institute for Health Research, published in Nature Medicine.  Trialed in… Read More

#News